Conference Proceedings

Efficacy of a third course of alemtuzumab in patients with active relapsing-remitting multiple sclerosis who experienced disease activity after the initial two courses: pooled analysis of CARE-MS I and II

A Traboulsee, A Boster, AD Bass, R Berkovich, G Comi, O Fernandez, HJ Kim, V Limmroth, J Lycke, RAL Macdonell, B Sharrack, P Vermersch, H Wiendl, T Ziemssen, M Melanson, N Daizadeh, BV Singer

MULTIPLE SCLEROSIS JOURNAL | SAGE PUBLICATIONS LTD | Published : 2017

University of Melbourne Researchers

Grants

Funding Acknowledgements

Study support: Sanofi and Bayer HealthCare Pharmaceuticals.